skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Abemaciclib (Code C97660)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Abemaciclib

Definition: An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.

Label: Abemaciclib

NCI Thesaurus Code: C97660 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3852841  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2-Pyrimidinamine, N-(5-((4-ethyl-1-piperazinyl)methyl)-2-pyridinyl)-5-fluoro-4-(4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl)

External Source Codes: 
CAS Registry Number 1231929-97-7 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 706364
PDQ Open Trial Search ID 706364 (check for NCI PDQ open clinical trial info)
UMLS CUI C3852841

Other Properties:
     Name Value (qualifiers indented underneath)
code C97660
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom